Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

22

Revenue 2014

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Novartis' Rydapt approval ends long AML therapy drought

Novartis' Rydapt approval ends long AML therapy drought

Daiichi Sankyo's quizartinib - acquired along with Ambit Biosciences' for $410m in 2014 - and Arog Pharma's crenolanib are both in phase III testing in FLT3-positive AML.

Japanese pharma pulls no punches with post-Brexit UK

Japanese pharma pulls no punches with post-Brexit UK The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and

Deal Watch March 2017

Deal Watch March 2017 Resarci out-licensed ACAT-1 to Xynomic, as detailed above, and Daiichi Sankyo paid $4m upfront, committed $8m in research funding and further research, development and commercialisation milestone payments for the ... 20. Heptares/ Sosei Group. Daiichi

Hookipa Biotech appoints new global head of research and development

Hookipa Biotech appoints new global head of research and development Hookipa Biotech appoints new global head of research and development. Dr Igor Matushansky joins the firm from Daiichi Sankyo. ... Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early

Xarelto beats aspirin for recurrent blood clots

Xarelto beats aspirin for recurrent blood clots rival NOAC Eliquis (apixaban) from Pfizer and Bristol-Myers Squibb (BMS) with 42.5%, well ahead of third place Pradaxa (dabigatran) from Boehringer Ingelheim and Daiichi Sankyo's new entrant Savaysa

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Reaching your audiences, wherever they are. Ashfield is an international provider of outsourcing solutions to the pharmaceutical industry, dedicated to...

Latest intelligence

The new pharma marketing playbook
Learn about the 5 areas that must be in your pharma marketing playbook...
Pharma needs to evolve from customer-centricity to stakeholder-centricity
Customer-centricity and patient-centricity is no longer enough for pharma sales and marketing strategies as digital promises better customer experiences for all pharma stakeholders....
5 health behavioural factors to incorporate in your marketing
Achieve real health behaviour change by including these elements in your pharmaceutical marketing....

Infographics